首页 › 基金 › NEXPOINT ASSET MANAGEMENT, L.P. › CPRX

NEXPOINT ASSET MANAGEMENT, L.P. 对 CPRX 的持仓历史

CATALYST PHARMACEUTICALS INC

NEXPOINT ASSET MANAGEMENT, L.P. 在 Q2 2026 的 13F 申报中披露持有 CPRX(CATALYST PHARMACEUTICALS INC)1,602,557 股,市值约 US$50.4M,约占其申报组合的 3.45%,在其申报持仓中市值排名第 13 位。 NEXPOINT ASSET MANAGEMENT, L.P. 于 Q2 2026 首次申报该持仓。

最新持仓 (Q2 2026)1.60M 股
申报持仓市值$50.37M
组合权重3.45%
首次申报Q2 2026
最近变动新进
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

NEXPOINT ASSET MANAGEMENT, L.P. 对 CPRX 的持仓演变

NEXPOINT ASSET MANAGEMENT, L.P. 于 Q2 2026 首次披露 CPRX 持仓:1,602,557 股(约 US$50.4M)。

逐季持仓明细

季度股数金额变化
Q2 2026 1.60M $50.37M 新进

关于 CPRX 与 13F 数据

CPRX(CATALYST PHARMACEUTICALS INC)的行业分类暂缺。我们追踪的基金中还有 42 只申报持有 CPRX,申报仓位最大的包括:GLAZER CAPITAL, LLC (US$113.2M), HBK INVESTMENTS L P (US$88.6M), Polar Asset Management Partners Inc. (US$36.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 CPRX 的基金

查看 CPRX 的全部基金持有人 →

常见问题

How long has NEXPOINT ASSET MANAGEMENT, L.P. held CPRX?

NEXPOINT ASSET MANAGEMENT, L.P. has disclosed CPRX holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is NEXPOINT ASSET MANAGEMENT, L.P.'s current position in CPRX?

As of Q2 2026, NEXPOINT ASSET MANAGEMENT, L.P. holds 1.60M shares of CPRX (CATALYST PHARMACEUTICALS INC), valued at $50.37M, representing 3.45% of its reported portfolio and ranking #13.

Has NEXPOINT ASSET MANAGEMENT, L.P. been buying or selling CPRX?

In the latest 13F filing (Q2 2026), NEXPOINT ASSET MANAGEMENT, L.P. newly opened its position in CPRX.

Which other funds hold CPRX?

Other major institutional holders of CPRX include GLAZER CAPITAL, LLC, HBK INVESTMENTS L P, Polar Asset Management Partners Inc., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.